收购换来持续亏损，康惠股份仲裁追讨2.66亿元业绩补偿款

Core Viewpoint - The company, Kanghui Pharmaceutical Co., Ltd., has initiated arbitration against Lai Xinsheng for a remaining performance compensation of 266 million yuan, stemming from a previous acquisition that has led to significant financial losses and uncertainties regarding future profits [1][2][3] Group 1: Acquisition and Performance Compensation - In September 2020, Kanghui acquired 51% of Shandong Youbang Biochemical Technology Co., Ltd. for 32.64 million yuan, with performance guarantees from Lai Xinsheng for net profits of 5 million, 10 million, and 20 million yuan for the years 2021 to 2023 [2] - Following an audit, Shandong Youbang reported a cumulative loss of 72.6377 million yuan from 2021 to 2023, leading to a compensation claim of 269 million yuan from Lai Xinsheng [2][3] - As of now, Lai Xinsheng still owes Kanghui 266 million yuan in performance compensation, despite partial payments made through a third party [3] Group 2: Financial Performance and Losses - Kanghui has reported continuous losses over the years, with revenues of 492 million yuan, 673 million yuan, and 562 million yuan from 2022 to 2024, and corresponding losses of 63.06 million yuan, 26.16 million yuan, and 89.63 million yuan [8] - In the first three quarters of 2025, Kanghui's revenue declined by 12% to 356 million yuan, with a net loss of 133 million yuan, attributed to the write-off of receivables from its subsidiary, Shaanxi Youbang [8] Group 3: Operational Challenges - Shaanxi Youbang, a subsidiary of Kanghui, has faced operational difficulties, including a complete shutdown of production due to market competition and ongoing losses, leading to plans for bankruptcy restructuring to improve its financial situation [5][6] - The company has also made significant provisions for bad debts related to Shaanxi Youbang, totaling 121 million yuan, indicating a challenging financial outlook [6] Group 4: Corporate Changes - In September 2023, Kanghui underwent a change in control, with the major shareholder shifting from Shaanxi Kanghui Holdings to Jiaxing Yuehe Zhichuang Technology Partnership, which has implications for its strategic direction [7] - Following the change in control, the company rebranded from "Kanghui Pharmaceutical" to "Kanghui Co., Ltd." to better reflect its long-term development strategy [7]